ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing ...

As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

SH-110, a liquid cancer treatment for glioma, earned orphan drug status from the FDA, helping patients who struggle to ...

President Donald Trump’s “big, beautiful bill,” which he signed into law earlier this month, includes major wins for business ...

BrainStorm Cell Therapeutics Inc. shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced ...

Mesoblast's shares rallied ahead of the bell Friday after the Australian regenerative medicine company disclosed initial sales of Ryoncil, its recently launched mesenchymal stromal cell therapy for ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

INDIAN pharmaceutical company MSN Laboratories has established a wholly owned subsidiary in Jamaica, positioning the country ...

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple ...

Prescient Therapeutics has signalled its position as one of the most advanced oncology companies on the ASX, according to ...

Brainstorm Cell Therapeutics ( ($BCLI) ) has provided an update. On July 16, 2025, BrainStorm Cell Therapeutics Inc. was notified by Nasdaq of its ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market ...